Table 1.
Baseline clinical characteristics comparison of the 131 cases between training set and testing set, and responders and non-responders.
| Variables | Sample | Training set | Testing set | P Value | Responders | Non-responders | P Value |
|---|---|---|---|---|---|---|---|
| Age, median | 62 (57, 68) | 62 (55, 68) | 0.554 | 62 (55, 69) | 62 (57, 66) | 0.99 | |
| Sex, No. (%) | 0.915 | 0.21 | |||||
| Male | 112 | 78 (85.71%) | 34 (85.00%) | 70 (88.61%) | 42 (80.77%) | ||
| Female | 19 | 13 (14.29%) | 6 (15.00%) | 9 (11.39%) | 10 (19.23%) | ||
| Smoking history, No. (%) | 0.397 | 0.49 | |||||
| Non-smokers | 36 | 27 (29.67%) | 9 (22.50%) | 20 (25.32%) | 16 (30.77%) | ||
| Smokers | 95 | 64 (70.33%) | 31 (77.50%) | 59 (74.68%) | 36 (69.23%) | ||
| Pathological type, No. (%) | 0.954 | 0.32 | |||||
| Adenocarcinoma | 66 | 46 (50.55%) | 20 (50.00%) | 37 (46.84%) | 29 (55.77%) | ||
| Others | 65 | 45 (49.45%) | 20 (50.00%) | 42 (53.16%) | 23 (44.23%) | ||
| Distant metastasis, No. (%) | 0.655 | 0.001 | |||||
| Absence | 26 | 19 (20.88%) | 7 (17.50%) | 23 (29.11%) | 3 (5.77%) | ||
| Presence | 105 | 72 (79.12%) | 33 (82.50%) | 56 (70.89%) | 49 (94.23%) | ||
| Treatment strategy, No. (%) | 0.903 | 0.31 | |||||
| Immunotherapy | 71 | 49 (53.85%) | 22 (55.00%) | 40 (50.63%) | 31 (59.62%) | ||
| Combination therapy | 60 | 42 (46.15%) | 18 (45.00%) | 39 (49.37%) | 21 (40.38%) |